Evolving Paradigms in Melanoma Therapy
November 6, 2015
Learning Objectives
- Describe the mechanism of action for talimogne laherparepvec (T-VEC)
- Describe how checkpoint inhibitors, both CTLA-4 and PD-L1, alter the body’s immune response to melanoma cells
- Describe potential toxicities associated with checkpoint inhibitors, including etiology of these toxicities and management and/or prophylaxis
- Explain how checkpoint inhibitors differ from other available treatment options for metastatic melanoma, including kinase inhibitors and cytotoxic chemotherapy
- Discuss the role of the advanced practitioner as part of the collaborative practice team in caring for patients on immunotherapy treatments
United States
Anthony J. Olsznaski, MD, RPH
Brianna Hoffner, MS, ANP-BC, AOCNP
Available Credit
- 1.00 AANP
- 0.83 Pharmacology
- 1.00 ACPE
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance
- 1.00 ANCC